Views & Analysis

Taking stock of NHS medicines optimisation

Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at local level, says NHS Gloucestershire CCG’s Ellen Rule. Medicines optimisation aims to improve health outcomes, service quality, and sustainability by ensuring patients are taking …

Taking stock of NHS medicines optimisation Read More »

EFPIA: Partnership is the key to healthcare’s biggest challenges

The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning collaborations involving Pfizer, Janssen, Novartis and more. Partnership is the key to unlocking the solutions to our major healthcare challenges, and “no player has a monopoly on good ideas”. That’s according to the European Federation of Pharmaceutical …

EFPIA: Partnership is the key to healthcare’s biggest challenges Read More »

The tech revolution reshaping European healthcare

The European health tech industry has made a “quantum leap” into using digital health technology due to the pandemic with the help of a growing number of trailblazing entrepreneurs, according to AlbionVC. The London-based venture capital firm provides a useful overview of how healthcare has changed over the last decade, and where digital health is …

The tech revolution reshaping European healthcare Read More »

France’s biotech ecosystem is primed for growth – it’s time to feed it

After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman. Prior to the pandemic, our homegrown entrepreneurs felt too often they had to go abroad to the United States to get the funding they needed, government support for clinical trials …

France’s biotech ecosystem is primed for growth – it’s time to feed it Read More »

Preparing for a post-pandemic world

Janssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can become stronger as we emerge from the pandemic. There’s plenty of talk about a post-COVID world right now, which can seem strange when so many places are still feeling the impact or remain in the grip of …

Preparing for a post-pandemic world Read More »

Biotech Insight podcast: Overcoming planning challenges in oncology

The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology. Joining Dominic Tyer for this instalment of Biotech Insight are Prithu Somani, senior manager of forecasting and business analytics at Genmab, and Kantar Health’s vice president of …

Biotech Insight podcast: Overcoming planning challenges in oncology Read More »

4 ways emerging pharma companies can harness marketing content

Rapid creation of compliant marketing content is increasingly important and there are ways emerging pharma companies can stay ahead of the game – despite having fewer resources than bigger firms. A new pharma marketing content ebook from Veeva looks at best practices for building a content foundation that can enable long-term growth. It explains how …

4 ways emerging pharma companies can harness marketing content Read More »

How blockchain can revolutionise medical records and save lives

Balancing medical privacy with ease of access for healthcare professionals is a challenge, but technology could provide the solution, says Aleph Zero Foundation’s Matthew Niemerg. Most people don’t think of healthcare when they hear blockchain, and that’s understandable; the technology so far hasn’t gone much beyond financial instruments – at least, not in the eyes …

How blockchain can revolutionise medical records and save lives Read More »

Prof Nigel Osborne: Science is catching up with ‘medical music’

The internationally recognised composer, peace worker and musical therapy pioneer tells pharmaphorum how his emerging field stands at an important threshold. History provides a wealth of commentary on the emotional value of music. One of the earliest came from Plato, who concluded that “rhythm and harmony find their way into the inward places of the …

Prof Nigel Osborne: Science is catching up with ‘medical music’ Read More »

Targeting COVID-19 and cancer with immunotherapy advancements

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes due to the emergence of biologics – particularly monoclonal antibodies – as therapies for a wide variety of diseases and infections. Monoclonal antibodies (mABs) are highly specific therapies associated with …

Targeting COVID-19 and cancer with immunotherapy advancements Read More »

How pharma can help the post-COVID recovery of European cancer care

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute phase of the pandemic, with a focus on the way in which treatment strategies were altered. The publication, which has been supported by Accord Healthcare, also provides a series of …

How pharma can help the post-COVID recovery of European cancer care Read More »

External control arms and debunking real-world data myths

For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies to patients faster, say COTA Viraj Narayanan and Karla Feghali from ConvergeHEALTH by Deloitte. External control arms (ECAs) – also known as synthetic control arms – are based on real …

External control arms and debunking real-world data myths Read More »

Nine ways to keep focus and boost your pharma career

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. His second column addresses the vital importance of prioritisation. There used to be times when every single task seemed important. Naturally. I’m a perfectionist …

Nine ways to keep focus and boost your pharma career Read More »

Amplifying the patient voice for better engagement, recruitment and retention

Everyone is familiar with the phrase ‘patient-centricity’ but, where it might once have been seen as a ‘checkbox exercise’, it has gained preeminent status in the era of COVID-19, says Prime Global’s Ross Jackson. The pandemic has transformed many aspects of our industry and one area that change has come to is patient engagement within …

Amplifying the patient voice for better engagement, recruitment and retention Read More »

Improving access to treatments in challenging markets

The COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at pace and speed. Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute …

Improving access to treatments in challenging markets Read More »

Blueprints for UK pharma-NHS joint working

Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As the NHS begins to recover from the biggest crisis in its history, the biopharmaceutical industry is stepping up to the plate to offer its support and a new online repository of …

Blueprints for UK pharma-NHS joint working Read More »

Vertex’s Nicola Massey: the pharmaphorum podcast

In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland. Having joined the biopharmaceutical company only fairly recently, they discuss her career path to Vertex, and also what it was like to join virtually – something that’s Increasingly common for many people …

Vertex’s Nicola Massey: the pharmaphorum podcast Read More »

Organon Makes Women’s Health a Priority

Simon Nicholson tells us how Organon, a new women’s healthcare company, is working to effect positive change globally by listening to women about their health care needs and allowing that information to drive their business development strategy. As Merck looked to expand its portfolio, it was determined that there’s a huge problem and need, particularly …

Organon Makes Women’s Health a Priority Read More »

Does draft RCT guide set the scene for future trials?

A common set of standards for randomised clinical trials (RCTs) aims to help researchers develop the drugs and interventions of the future – no matter what they do or where they are based. The Good Clinical Trials Collaborative (GCTC) has published a draft guidance document, and is asking for the life sciences sector to make …

Does draft RCT guide set the scene for future trials? Read More »

Health Innovators: PureTech Health’s Daphne Zohar

In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. They discuss the publicly-listed biotech’s pipeline projects and focus on the BIG (brain-immune-gut) axis as well as PureTech’s interest in digital therapeutics. Daphne explains how she built an impressive team of board …

Health Innovators: PureTech Health’s Daphne Zohar Read More »

From start to finish – digitising clinical trials

Over the past two years, the pharma industry’s demand for automated research solutions has increased significantly and, particularly when it comes to clinical trial design, the need has never been greater. This shift to digitised approaches has been triggered by some persistent challenges faced by those companies still reliant on applying manual processes. “A few …

From start to finish – digitising clinical trials Read More »

Organicell on regenerative medicine: the pharmaphorum podcast

In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative Medicine. They looked at the development of regenerative medicine and where Organicell hopes to add to that field. Then, with the company pivoting to try and help tackle Covid, they …

Organicell on regenerative medicine: the pharmaphorum podcast Read More »

Shaping the future of ovarian cancer diagnosis with femtech

Israeli femtech start-up GinaLife is developing a platform of biomarker strategies supported by artificial intelligence and data science for the early detection of problems in women’s health. CEO and co-founder Inbal Zafir-Lavie tells pharmaphorum more. Six years ago, research scientist Inbal Zafir-Lavie tragically lost her 38-year-old sister Hava Zafir to colorectal cancer. Due to her …

Shaping the future of ovarian cancer diagnosis with femtech Read More »

A problem combination?

Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge for combination therapies. Combination therapies are now common in therapy areas like cancer. There have been cases where even if a new treatment used in combination were offered at zero cost to the NHS that it would …

A problem combination? Read More »

Delivering valuable independent medical education programmes

In the next instalment in EPG Health’s HCP engagement series, Abhi Chakravorty looks at medical education’s new trajectory and how to build programmes that are credible, engaging and impactful. In these times of turmoil there are some reassuring constants when it comes to independent medical education (IME), which continues to be appreciated by healthcare professionals …

Delivering valuable independent medical education programmes Read More »

Collaborate to simplify cancer trials and accelerate post-pandemic recovery

How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI Scotland cancer roundtable discussion. Work to get Scotland’s cancer services back to full strength following the pandemic has already begun, and the pharmaceutical industry has pledged to play its part. …

Collaborate to simplify cancer trials and accelerate post-pandemic recovery Read More »

Dental implant market: Top trends bolstering industry growth

People across the world, especially the population aged 65 years or older, are suffering from some form of a medical condition that results in tooth decay or loss. According to statistics released by the Centers for Disease Control and Prevention, around 70.1% of the population in North America was 65 years or more and was …

Dental implant market: Top trends bolstering industry growth Read More »

Predicting and improving clinical trial enrolment: A problem for psychiatry

Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a trial area with significantly high drop-out rates and poor patient recruitment. The reasons behind this problem, however, are rarely studied or understood. Despite this, new strategies devised over the last five years are beginning to reverse the …

Predicting and improving clinical trial enrolment: A problem for psychiatry Read More »

Evaluating methods targeting Protein-Protein Interactions

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them.  The latest advancements in methods targeting PPIs are designed to overcome the challenges limiting the conventional methods. Targeting PPIs offers another potential therapeutic target for diseases with complex biological …

Evaluating methods targeting Protein-Protein Interactions Read More »

SMA Awareness Month: How pharma and digital solutions can improve patient care

Spinal Muscular Atrophy (SMA) is a rare disease affecting the motor nerve cells in the spinal cord. It’s a debilitating condition that affects 1 per 8,000 to 10,000 people worldwide, impacting their ability to walk, eat, and breathe. SMA Type 1 represents an estimated 50% of all cases, for which life expectancy is less than …

SMA Awareness Month: How pharma and digital solutions can improve patient care Read More »

How to balance the patient voice atop the shifting plates of HTA

The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances in medical science, from genomics and gene therapies to artificial intelligence (AI), have transformed the healthcare landscape, and triggered a review of NICE’s methods and processes. Consultation on the proposals …

How to balance the patient voice atop the shifting plates of HTA Read More »

Cancer research faces uncertain post-COVID landscape

There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding and development going forward, says The Institute of Cancer Research, London’s Paul Workman. Cancer research in the UK risks facing a “perfect storm” of stalled work and reduced funding that …

Cancer research faces uncertain post-COVID landscape Read More »

Have a chat to help others through loneliness

Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s gone’ comes to mind. It’s only now, having been isolated, that we can appreciate how much small moments of contact with family and friends can mean. Bristol Myers Squibb’s Janice Creasy discusses how  and help reduce feelings …

Have a chat to help others through loneliness Read More »

Surprise pandemic lessons for pharma

Ask people in most western nations to think back to 2019 and consider what they would have said then about the potential impact of a pandemic on their everyday lives and my guess is that the vast majority of us would have had little insight into what would happen. Residents of Southeast Asia who had …

Surprise pandemic lessons for pharma Read More »

Health literacy in the time of COVID-19

In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health literacy has never been more important. Impetus Digital’s Natalie Yeadon explores why. Health literacy is a complex phenomenon that involves both individuals and their local …

Health literacy in the time of COVID-19 Read More »

Lessons from the first generation of cell and gene oncology trials

Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies. ICON’s Tamie Joeckel and Brandon Fletcher take us through best-practice approaches to CGT studies and discuss what the future could hold for this exciting area. Cell and gene …

Lessons from the first generation of cell and gene oncology trials Read More »

Why digital doctors are crucial for the future of primary care

Our primary care system is weathering a storm on several fronts. Demand is skyrocketing, with GPs delivering millions more appointments than in previous years and workload far outstripping pre-Covid-19 levels. Dr Dan Bunstone explores how innovation can help GPs overcome the current capacity squeeze in primary care and tackle patient backlog. Despite the misconception that general …

Why digital doctors are crucial for the future of primary care Read More »

COVID-19: We don’t need another hero

We’ve all got used to hailing healthcare staff as heroes over the past year. Of course they deserve every ounce of admiration, even though many are uncomfortable with the adulation. But the bigger question is whether this heroic status really represents a healthy situation? Someone once advised me that, when conducting due diligence on a …

COVID-19: We don’t need another hero Read More »

Oncology R&D: the patient insights we’re still missing, and how to catch up

Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring solutions now, and for your entire career, you have been taught that things must be done a certain way. Patient engagement is viewed by many as a nice-to-have rather than …

Oncology R&D: the patient insights we’re still missing, and how to catch up Read More »

Tackling the ‘disease of systemic racism’ in clinical trials

A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into sharp focus by COVID-19. Tackling it, however, has not been easy, thanks in no small part to the reasons being as complex as they are multi-faceted. But, according to the …

Tackling the ‘disease of systemic racism’ in clinical trials Read More »

Digital tools key to immuno-oncology’s future: report

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper. The whitepaper, ‘The Role of Digital Health in Immuno-oncology Therapy Development and Adoption’ from …

Digital tools key to immuno-oncology’s future: report Read More »

Virtual reality therapy: The future of chronic pain management?

Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? pharmaphorum speaks to Professor Christopher Eccleston from the University of Bath’s Centre of Pain Research to find out how digital therapeutics are shaping the future of pain management. A digital software developed by Finnish drugmaker Orion is aiming to address chronic pain …

Virtual reality therapy: The future of chronic pain management? Read More »

COVID-19: Celltrion’s therapeutic option

In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. pharmaphorum spoke to Kwon Ki-sung, Head of Celltrion’s R&D unit, to learn more. Celltrion’s COVID-19 therapeutic, CT-P59, is a monoclonal antibody (mAb) with activity against COVID-19. It was identified as a potential treatment through the screening of …

COVID-19: Celltrion’s therapeutic option Read More »

Oncology and a year of COVID: lessons for the future

COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting change in research, practice and education, says Lucid’s Frances O’Connor. The COVID-19 pandemic might finally be in its latter stages after a year and a half of disruption, but its …

Oncology and a year of COVID: lessons for the future Read More »

Ten tips on pharma time management

Oliver Stohlmann’s new Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. In this first instalment he tackles managing time. A month into exiting my career of over two decades in global life-science multinationals, I’m …

Ten tips on pharma time management Read More »

How hybrid virtual engagement is accelerating oncology communication

COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement needs to move away from an overreliance on real-time meetings, say experts from Within3. By making virtual meetings a necessity, COVID has forced pharma to adopt a more flexible, digitally-driven approach to stakeholder interaction – but in …

How hybrid virtual engagement is accelerating oncology communication Read More »

Build back better: US pharma and the future of healthcare

America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged …

Build back better: US pharma and the future of healthcare Read More »

Build back better: US pharma and the future of healthcare

America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged …

Build back better: US pharma and the future of healthcare Read More »

Enabling healthcare’s digital future

Debiopharm Innovation Fund’s Tanja Dowe on investing in digital health start-ups and supporting them on their rollercoaster rides to improve patient outcomes The weight of expectation hangs heavy over the digital health sector. Even before COVID-19 struck, shattering established societal and healthcare norms, much was expected from start-ups that could combine health and tech. Now, …

Enabling healthcare’s digital future Read More »

Virtual GP clinics – are they accessible as they need to be?

As the the pandemic accelerates a move towards remote doctors appointments, work still needs to be done to ensure that digital healthcare is easy and accessible. Sam Jansen explores the practical steps needed to ensure people are comfortable with virtual clinics and the tech involved. Behind the swathe of headlines lauding the way in which …

Virtual GP clinics – are they accessible as they need to be? Read More »

What HCPs think about health equity in cancer care

After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in healthcare. CREATION.co’s Mary Kangley explores what HCPs think about health equity in cancer care. The topic rose to significance in the American Society of Clinical Oncology (ASCO) whereby they updated …

What HCPs think about health equity in cancer care Read More »

Digital health developments: a new investment era for start-ups

Healthware Labs’ Kristin Milburn explores how digital health start-ups can harness the huge potential for the sector in a post-COVID world and the paths they need to take to grow their business. Digital health has come a long way in the past decade – and Kristin Milburn says that the sector could now be about …

Digital health developments: a new investment era for start-ups Read More »

Why pharma needs a revolution in culture

James Dempsey breaks down the misconception that culture can’t be measured, and gives tips for how companies can implement a clear culture strategy. In 2014, six years after the global financial crisis forced the world’s biggest financial institutions into some serious navel gazing, the CEO of a major international bank was despairing: “We’ve put in …

Why pharma needs a revolution in culture Read More »

NICE feedback?

The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review its methods and processes for evaluating technologies. As part of that work, NICE is engaging widely with stakeholders, including patient organisations. Leela Barham provides an independent view of patient organisations responses to a NICE online survey and …

NICE feedback? Read More »

Why pharma shouldn’t forget about sites in a post-COVID world

The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to understand the value proposition of the technologies and methodologies adopted, says Syneos Health’s Angela Hirst. Formerly an oncology nurse and now director of Sites and Patient Services at Syneos Health’s …

Why pharma shouldn’t forget about sites in a post-COVID world Read More »

Taking steps towards a data-driven future for health and social care

A new policy paper promises to make it easier for innovators and developers to build and deploy tech and AI solution. So, will it help make the vision of a data-driven health service a reality? COVID-19 “revolutionised” the health and care data space, and we have a duty to apply what we have learnt to …

Taking steps towards a data-driven future for health and social care Read More »

How digital pathways are changing healthcare

As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a more connected ecosystem between doctors, patients and pharma. Ampersand Health has been working in the space since 2015 and has seen it evolve from a niche approach with limited acceptance …

How digital pathways are changing healthcare Read More »

Rare disease: industry, patients and tech join forces on diagnosis

Takeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis. Diagnosis can sometimes be the most difficult part of a rare disease patient’s journey, and it’s with good reason that the process is often referred to as an ‘odyssey’ in these communities. “We’re dealing with very small populations of …

Rare disease: industry, patients and tech join forces on diagnosis Read More »

Accelerating the adoption of innovation in the NHS

Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. Scaling up the adoption of new interventions and technologies in the NHS has always been something of a challenge. But a review of approaches used by the Academic Health Science …

Accelerating the adoption of innovation in the NHS Read More »

A life sciences vision to deliver health, wealth and resilience for the UK

The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an extraordinary year of science versus disease, the UK has cemented itself at the forefront of the global response to COVID-19. What has been achieved in just 18 months is nothing …

A life sciences vision to deliver health, wealth and resilience for the UK Read More »

COVID-19 neutralising antibody tests – an integrated approach

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help life resume. Millions of tests for COVID-19 are taken worldwide every day, as they become an increasingly important tool for our return to normality. Testing programmes have been …

COVID-19 neutralising antibody tests – an integrated approach Read More »

Herd immunity is nice – but what about me?

Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. To-date, the battle against COVID-19 has been waged largely in the field of public health, using a series of binary, black-and-white thresholds to measure progress. The number of positive cases per 100,000 people, yes/no results on PCR tests, absence or presence of …

Herd immunity is nice – but what about me? Read More »

When biotech meets reality TV – Starton Therapeutics faces the Unicorn Hunters

Starton Therapeutics is bypassing the traditional venture capital route to raise money for its transdermal delivery technology that delivers medicine through the skin. pharmaphorum hears why the company decided to appear on a new reality investment show. A big clock times a 60 second countdown as biotech CEO Pedro Lichtinger delivers an elevator pitch to …

When biotech meets reality TV – Starton Therapeutics faces the Unicorn Hunters Read More »

Health Innovators: Eliot Forster, F-Star

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the lives of patients with cancer.     About the author Dr Paul Tunnah is chief content officer and UK managing director for Healthware Group, a next-generation integrated consulting group that …

Health Innovators: Eliot Forster, F-Star Read More »

Pharma’s use of synthetic biology could deliver radical innovation

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, …

Pharma’s use of synthetic biology could deliver radical innovation Read More »

Pharma’s use of synthetic biology could deliver radical innovation

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, …

Pharma’s use of synthetic biology could deliver radical innovation Read More »

COVID-19 vaccine development: Safety monitoring continues revolution in RWD

From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve outcomes for patients in need. In today’s feature, Dr. Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality.  Only a year after the emergence …

COVID-19 vaccine development: Safety monitoring continues revolution in RWD Read More »

COVID-19 vaccine development: Safety monitoring continues revolution in RWD

From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve outcomes for patients in need. In today’s feature, Dr. Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality.  Only a year after the emergence …

COVID-19 vaccine development: Safety monitoring continues revolution in RWD Read More »

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better …

Turning words into actions with patient engagement Read More »

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better …

Turning words into actions with patient engagement Read More »

Supporting and empowering carers to make their voices heard

There are an estimated nine million carers in the UK, and their contributions to society, individually and as a group, are unparalleled. Nadine van Dongen and Antonella Porta remind us why carers are the unrecognised backbone of our society. Every day, carers look after some of the most vulnerable people around us, attending to their …

Supporting and empowering carers to make their voices heard Read More »

Pandemic paves way for innovative hybrid healthcare

While the heroic abilities of the NHS have been on display throughout the COVID-19 pandemic, the last year has also exposed the longstanding limitations and frailties of our underfunded healthcare system, says Maya Ward. With an estimated 100,000 unfilled posts and staff turnover expected to increase due to emotional exhaustion, the health service’s workforce stands …

Pandemic paves way for innovative hybrid healthcare Read More »

Transforming pharma R&D with a scientist-centric approach to AI & automation

As biopharmaceutical products have become increasingly complex, both in design and in regulatory requirements, we need a new way of working. Markus Gershater looks at how automation and artificial intelligence (AI) can transform pharma R&D. Due to increasing complexity in R&D, pharma teams are under pressure to drive down costs and speed up time to …

Transforming pharma R&D with a scientist-centric approach to AI & automation Read More »

A roadmap for adopting New Science 

The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways and public-private partnerships drive innovation to address a common need. Can the biopharma industry step up again to shatter industry orthodoxy and create new pathways for innovation, access, and affordability? The adoption of …

A roadmap for adopting New Science  Read More »

How the patient voice is becoming vital for drug approval

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read below for …

How the patient voice is becoming vital for drug approval Read More »

Keeping clinical trial data safe – handling cybersecurity in a risky world

The development of vaccines for COVID-19 has been a masterclass in effective collaboration and applied digitisation in healthcare. However the increased complexity and involvement of different parties, exposes manufacturers to heightened threat levels. Abel Archundia discusses how COVID-19 has highlighted the importance of securing clinical trials against cyber threats. A process that historically would have …

Keeping clinical trial data safe – handling cybersecurity in a risky world Read More »

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn, explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not survive. The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are …

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities Read More »

Ensuring accessibility: Crossing the digital divide in healthcare

“Rarely does the answer come from the boardroom” – what can user experience teach us about building accessible digital health? No one should be left behind as the world embraces digital healthcare say leading user experience, voices. The experts discussed the benefits and merits of co-creation during a session on bridging the digital divide, held …

Ensuring accessibility: Crossing the digital divide in healthcare Read More »

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. Home to over 60% of the world’s population, Asia Pacific (APAC) is not a region the biopharma industry can afford to ignore. Dr Jay Mei, founder and …

Country focus: China & APAC’s growing medical needs bring opportunities and challenges Read More »

Experts discuss the field force’s customer-centric future

The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has dramatically accelerated that. In a recent pharmaphorum webinar, in partnership with Axtria, commercialisation experts from across the industry discussed how the right field force training and execution in combination with …

Experts discuss the field force’s customer-centric future Read More »

“A long way to go” for digital health reimbursement

A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to market. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: In many ways, the healthcare sector is still wrestling …

“A long way to go” for digital health reimbursement Read More »

Value-based healthcare: Pandemic learnings and future musings

In the second part of our series from the ‘Patient Experience: Empathy and Innovation’ Digital Summit, we look at what COVID-19 can teach us about designing truly value-based healthcare.  Discussions of value-based healthcare provider contracts are often technical and far removed from the patient – but COVID has given us a chance to connect the …

Value-based healthcare: Pandemic learnings and future musings Read More »

Time for a NICE change

The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the world has changed over its history, NICE is coming to the end of a period of review and consultation on their processes and methods. Leela Barham takes stock. …

Time for a NICE change Read More »

Changing focus to cachexia may be key to improved cancer outcomes

Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses the historial challenges to developing a therapeutic for this condition and what may finally be on the horizon.  Until recently, cancer research and resulting therapeutic approaches have focused on one …

Changing focus to cachexia may be key to improved cancer outcomes Read More »

BIO-Europe Spring Digital: Big data and AI panel discussion

The combination of big data and artificial intelligence/machine learning is a powerful one and nowhere more so than in healthcare. As part of BIO-Europe Spring Digital, pharmaphorum founder Dr. Paul Tunnah moderated a panel discussion about big data, AI and applications in the real world. The expert panel explored the evolving applications of big data …

BIO-Europe Spring Digital: Big data and AI panel discussion Read More »

What HCPs think about blood clots linked to COVID-19 vaccines

In the latest edition of What HCPs Think, CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. The formation of blood clots is a necessary process in order for the body to repair damage caused by injury and to slow down bleeding. However, when blood clots form inappropriately, …

What HCPs think about blood clots linked to COVID-19 vaccines Read More »

Are microtaggants the key to making medicines smarter?

Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. The dramatic rise in online drug sales during the COVID-19 pandemic has increased the supply of counterfeit drugs, and many companies are now considering the addition of on-dose authentication for high-risk or high-value products. To implement …

Are microtaggants the key to making medicines smarter? Read More »

Pharma’s post-COVID prospects: the pharmaphorum podcast

In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season. Meade talked about the prospects for the industry as the UK and other economies beginning to recover from the devastating pandemic. He discussed how COVID vaccines have …

Pharma’s post-COVID prospects: the pharmaphorum podcast Read More »

Closing the feedback loop to drive patient experience improvements

Is collecting near real time data the key to unlocking improvements in patient experience and national benchmarking? Small things can go a long way in terms of improving patient experience, but healthcare facilities cannot fix what they don’t know is broken. In the first of our series of articles from the Patient Experience: Empathy and …

Closing the feedback loop to drive patient experience improvements Read More »

Now what? The future of clinical trials after the pandemic

Sheila Rocchio highlights four key areas life sciences must improve on as an industry to drive real change in how clinical trials are conducted. This is definitely a time for the life sciences industry to be proud of our accomplishments. The way in which the industry came together to support the development of the COVID-19 …

Now what? The future of clinical trials after the pandemic Read More »

Rethinking access barriers to innovation

Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. This article appears in our digital magazine Deep Dive: Market Access 2021. Read on …

Rethinking access barriers to innovation Read More »

How diversity can help life sciences advance its lifesaving solutions

Paula Parfitt discusses the importance of workplace diversity and how life science companies can build a thriving, diverse workforce. Diversity, equity and inclusion (D, E & I) is a sensible business choice with significant commercial benefits. A homogenous workforce has a smaller pool of collective experience, meaning that when problems arise, collective creativity and innovation …

How diversity can help life sciences advance its lifesaving solutions Read More »

New Cell & Gene Therapy Collective seeks to boost UK adoption

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to wider adoption. These challenges often arise because these therapies go through the same value assessment processes as less complex medicines, and the infrastructure …

New Cell & Gene Therapy Collective seeks to boost UK adoption Read More »

AI, big data and real world evidence – the challenges and opportunities

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations in medicine. A recent pharmaphorum webinar, held in partnership with Savana and BREATHE – the Health Data Research Hub for Respiratory Health, heard that RWE is also accelerating the development of new and innovative therapies …

AI, big data and real world evidence – the challenges and opportunities Read More »

AI meets RWE: The future of drug assessment?

Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma and regulators. This article appears in out digital magazine Deep Dive: Market Access 2021. Read below for a preview: Real world evidence (RWE) is rapidly evolving. Having gone from being …

AI meets RWE: The future of drug assessment? Read More »

What is modular content and why do pharma marketers need it NOW?

Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. It is a newer concept for pharma marketers, however, who are now turning to modular solutions in response …

What is modular content and why do pharma marketers need it NOW? Read More »

Listening to ultra-rare disease communities

When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare diseases, PTC Therapeutics is familiar with the challenges. The company prides itself on a patient-centric approach to treatment but there can be significant hurdles in patients accessing potentially life-changing treatments. …

Listening to ultra-rare disease communities Read More »

Arecor heads for London Stock Exchange with drug reformulation strategy

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients.  Arecor Therapeutics is the latest company aiming to take advantage of the “feelgood” factor in the biotech sector, which …

Arecor heads for London Stock Exchange with drug reformulation strategy Read More »

Report calls for better work culture in UK research

Create a positive working culture for the UK’s researchers, or watch the country’s standing as an innovation leader crumble, says new report. From the Oxford vaccine to the RECOVERY trial, all eyes have been on the triumph of British science in recent months. But future success is at risk if we do not create a …

Report calls for better work culture in UK research Read More »

How to improve payer engagement with tailored value communication

Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic areas. However, value can mean different things to different payers. In this article, Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing …

How to improve payer engagement with tailored value communication Read More »

The Online Safety Bill: a step towards digitally safe mental health support

The UK government’s Online Safety Bill has been a hot and contentious topic of discussion over the past year, but last week it was finally announced and included in the Queen’s Speech. For Mental Health Awareness Month, Tim Barker looks at why a new bill could be a step towards digitally safe mental health support.  …

The Online Safety Bill: a step towards digitally safe mental health support Read More »

Key insights for a successful first-time product launch

Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning and an agile approach, they can be more successful than they realise, says Veeva’s Ian Hale. He takes us through the challenges of a successful launch and explains what pre-commercial …

Key insights for a successful first-time product launch Read More »

From representation to empowerment: Putting patients at the centre of medicine reimbursement

Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this. This article appears in full in our digital magazine Deep Dive: Market Access 2021. Read below for a sneak-peak: The reimbursement landscape in Europe is complex. There …

From representation to empowerment: Putting patients at the centre of medicine reimbursement Read More »

Designing HCP engagement for the next normal

Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Restrictions to in-person face-to-face interactions have resulted in increased use of remote and digital channels. Many life sciences companies have begun 2021 by reviewing how they respond to the longer-term impact of this change, and its …

Designing HCP engagement for the next normal Read More »

How will NICE fare in a post-Brexit world?

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. This article appears in our digital magazine, Deep Dive: Market Access …

How will NICE fare in a post-Brexit world? Read More »

Health Innovators: Teresa Arroyo-Gallego, nQ Medical

In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist at artificial intelligence technology company nQ Medical. As a researcher in the biomedical engineering lab of the Massachusetts Institute of Technology (MIT), Teresa leads a team developing the neuroQWERTY technology to detect early signs of motor decline in …

Health Innovators: Teresa Arroyo-Gallego, nQ Medical Read More »

Inside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimab

Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab. In an interview with pharmaphorum’s news editor Richard Staines, chief operating officer Arnout Ploos van Amstel revealed how the biotech and its “mystery CEO” managed to swoop for the drug ahead of big pharma rivals. …

Inside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimab Read More »

Why health tech is a win for mental health

For Mental Health Awareness Week (10 May 2021 – 16 May 2021) myGP discusses the benefits of the healthcare system becoming digitised and the impact this will have on mental health care.  The UK government has pledged an ambitious programme of revolutionising mental health over the next three years, seeing all mental health service providers …

Why health tech is a win for mental health Read More »

4 ways to embed data-driven best practice in pharma HCP communications

Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for pharma companies to maintain up-to-date customer data. Over the 12 months to December 2020 the number of global Veeva CRM Engage Meetings increased sixfold, while those held in Europe saw an eight-fold increase – with 200,000 remote …

4 ways to embed data-driven best practice in pharma HCP communications Read More »

Research predicts the post-COVID landscape for HCP engagement

IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes. This article appears in full in Deep Dive: Market Access 2021. Read a preview below: Recent ChannelDynamics data from IQVIA shows that while there has been a marked …

Research predicts the post-COVID landscape for HCP engagement Read More »

Is digital mental health the key to tackling a deepening crisis?

In an exclusive feature for pharmaphorum, British Liberal Democrat politician, solicitor and mental health campaigner Sir Norman Lamb discusses why digital mental health services can help tackle the escalating mental health crisis. The COVID-19 pandemic has had a severe negative effect on the population’s mental health across the globe. We know that government measures like …

Is digital mental health the key to tackling a deepening crisis? Read More »

A year on: pandemic driven trends in HCP engagement

IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears in full in this month’s Deep Dive digital magazine on Market Access. Here is a preview: As we reach the end of the first quarter of 2021, our customers continue …

A year on: pandemic driven trends in HCP engagement Read More »

How a lack of mental health diagnosis is affecting young men

As lockdown gradually eases, things are starting to look up but the lasting impact COVID-19 has had on our wellbeing remains. During Mental Health Awareness Month we look at the mental health stigma amongst men. To say we’re in the midst of a mental health crisis is not an exaggeration. Mental health concerns have been …

How a lack of mental health diagnosis is affecting young men Read More »

Why relationships are key in rare disease patient engagement

Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a broader view of their lived experiences, says Xperiome’s Jeremy Edwards. It is difficult to get data on rare diseases and the people who live with them by their very nature. …

Why relationships are key in rare disease patient engagement Read More »

Tackling diabetes & ALS with cell therapy

Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral sclerosis (ALS) and diabetes. Catherine Longworth spoke with Kadimastem’s head of diabetes research, Kfir Molakandov to find out more. In the 1990s, when the first transplant of islets took place, …

Tackling diabetes & ALS with cell therapy Read More »

Creating a global life sciences superpower from the lessons of COVID

It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry and apply it to creating a “life sciences superpower”, says health secretary Matt Hancock. The UK’s life sciences industry has “achieved in months what usually takes years” – and in doing so has built a solid foundation …

Creating a global life sciences superpower from the lessons of COVID Read More »

A digital health roadmap for pharma, medical devices and insurance tech

COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for pharma, medical device and insurance tech companies. The key trends for these sectors are identified and analysed in a new white paper from Healthware Group that offers guidance on how companies can best adjust to the new …

A digital health roadmap for pharma, medical devices and insurance tech Read More »

Hidden compliance risks for life sciences companies

The life sciences history industry has some unique challenges when it comes to compliance. But if you think third party compliance risks are bad, don’t take your eye off fourth and fifth parties, says Allan Matheson. Early life science pioneers in foreign markets earned a reputation for lax ethical behaviour, making them a prime target …

Hidden compliance risks for life sciences companies Read More »

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce …

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast Read More »

Deep Dive: Market Access

It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks. …

Deep Dive: Market Access Read More »

Not just COVID-19 vaccines: 5 things that cause blood clots

Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the most common causes of blood clots and how we can prevent them. Over 11 million doses of COVID-19 vaccines have been given across the UK, with blood clotting observed …

Not just COVID-19 vaccines: 5 things that cause blood clots Read More »

Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace

Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care. Founder and CEO Konstantin Mehl spoke to pharmaphorum’s news editor Richard Staines about why these treatments will be in demand as the world emerges from the pandemic. To say that …

Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace Read More »

The role of data science and text mining in the search for new therapies

Today, most drug discovery programmes begin with the identification and validation of disease modifying biological targets. The primary way to uncover these targets is through searching and reviewing published scientific literature. Eric Gilbert explores how data science techniques like text mining are speeding up research into areas such as pancreatic cancer. The increasing rate of …

The role of data science and text mining in the search for new therapies Read More »

Growing up different and not knowing why: My experience of rare vascular disorder KTS

Protracted diagnostic odysseys don’t only block access to rare disease treatments, they also leave people facing emotional turmoil all alone. Growing up in Glasgow, Linsey Brady “felt like a freak” and did everything she could to hide what she was told was a vascular deformation on her leg from the rest of the world. She …

Growing up different and not knowing why: My experience of rare vascular disorder KTS Read More »

Can your typing patterns reveal if you have Alzheimer’s?

The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now the team behind it is looking to expand into the notoriously-difficult area of dementia. Teresa Arroyo-Gallego tells us about the science behind the technology and how the team hopes to reshape cognitive screening.  While many disease areas …

Can your typing patterns reveal if you have Alzheimer’s? Read More »

AI is having a productive time in pharma and healthcare

Two years ago the use of AI in pharma and healthcare looked to be quickly heading for what Gartner’s Hype Cycle model would term the Plateau of Productivity. After the COVID-powered digital transformations of both pharma and healthcare, there can be little doubt that artificial intelligence is already having a productive time across our sector. …

AI is having a productive time in pharma and healthcare Read More »

Collaboration is key to advancing cell therapy research

Dr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company works with researchers and physicians across Europe to expand patient access to cell therapy. This thought leadership series has been paid and developed by Kite, a Gilead Company. Cell therapy is a treatment involving the genetic modification …

Collaboration is key to advancing cell therapy research Read More »

Big data and cell therapy development: the pharmaphorum podcast

In the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr Darrin Disley, who’s the CEO of Mogrify. The UK biotechnology company is aiming to transform the development of cell therapies using a systematic direct cell conversion & maintenance platform powered by big-data. Darrin discusses the story behind Mogrify’s technology and his …

Big data and cell therapy development: the pharmaphorum podcast Read More »

The next five years of NICE: Challenges, opportunities, and the future of technology assessment

If NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and more ready to adapt – and COVID-19 has proved that it is more than capable of doing so. NICE is about to undergo a complete transformation in a bid to get ready – and stay ready – …

The next five years of NICE: Challenges, opportunities, and the future of technology assessment Read More »

What comes next: digital transformation in B2B life sciences sales

As the contours of a post-pandemic world begin to take shape, those working B2B sales in the life sciences acknowledge that the industry must adapt to some permanent shifts. Mert Yentur looks at what is next for the industry. Even prior to COVID-19, sales teams reckoned with traditional online-only CRM systems that didn’t align well …

What comes next: digital transformation in B2B life sciences sales Read More »

Three pillars of post-pandemic launch excellence

IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity for companies to focus on and address in 2021. It is undeniable that 2020 was a particularly challenging year to launch non-COVID innovative prescription medicines. The launch environment was directly impacted by the COVID-19 pandemic, which hit …

Three pillars of post-pandemic launch excellence Read More »

Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation

When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides itself on having an open, collaborative, “science first” approach to help ensure breakthrough discoveries have the very best chance of long-term success in bringing new treatment options to patients worldwide. “Our mission is to turn innovative science …

Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation Read More »

GDPR represents an “urgent threat” to the EU’s research leadership role

More than 5,000 collaborative studies were thwarted by GDPR rules in 2019 – but is there a way to protect sensitive data while still allowing international health research to thrive?  A coalition of European academy networks has called upon European Union (EU) leaders to rethink how General Data Protection Regulation (GDPR) rules are applied to …

GDPR represents an “urgent threat” to the EU’s research leadership role Read More »

Cytisinicline – the solution to stop smoking?

Whether present in electronic or combustible cigarettes, nicotine is a highly addictive substance. Dr Cindy Jacobs, chief medical officer of Achieve Life Sciences discusses the potential of cytisinicline therapy for smoking cessation.  Although e-cigarettes are considered a less dangerous alternative to combustible cigarettes, they can still result in, or sustain, nicotine addiction, for which the …

Cytisinicline – the solution to stop smoking? Read More »

The power of communication: engaging diverse groups in healthcare

Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society – especially in healthcare. Page & Page’s Lisa Jane Lishman outlines why communication and the strategies behind it need to be more personal to ensure that people …

The power of communication: engaging diverse groups in healthcare Read More »

The next generation of immunotherapy? Innate Pharma targets NK cells

Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer. Catherine Longworth spoke to CEO Mondher Mahjoubi to find out the science behind this next generation of immunotherapies.  Founded in 1999, Marseille-based company Innate Pharma is on a mission to develop immunotherapies that take advantage …

The next generation of immunotherapy? Innate Pharma targets NK cells Read More »

COVID heralds a faster future for drug development (if stakeholders can collaborate)

COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI.  The 2021 WIRED Health conference took a broad view …

COVID heralds a faster future for drug development (if stakeholders can collaborate) Read More »

Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. He spoke to pharmaphorum’s news editor Richard Staines to outline his plans to create a European biotech powerhouse.  The last ten years has seen Denmark’s Genmab become one of biotech’s big success stories. Under the …

Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab Read More »

What Is The Best Way to Incentivise a Digital-First Sales Team?

Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The issue with KPIs is they can be very ineffective. If clearly defined they will get you results, but if not, they can just reinforce the wrong behaviours. The difficulty is to define the right ones. Bottomline is …

What Is The Best Way to Incentivise a Digital-First Sales Team? Read More »

Country focus: Hungary carves out a niche in digital pharma

AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. Hungarian company, Turbine, is taking an alternative approach …

Country focus: Hungary carves out a niche in digital pharma Read More »

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

Alexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and vulnerable” leadership, the surprising impacts of COVID and the promising future for treating patients with rare diseases.  Alexion is a somewhat unique pharma company in that it focuses almost entirely on rare diseases – and although this …

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease Read More »

Transformational therapies demand a new mindset

Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Such interventions take the need for robust value claims to a completely different level, with important implications for the evidence companies need to collect, and how they collect and communicate it. Chris Gray leads Innovation and Ventures for Adelphi’s …

Transformational therapies demand a new mindset Read More »

NICE methods and process review aims to create fertile ground for innovation

The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK? Amanda Barrell spoke to Dr Paul Catchpole, director of value and access policy at the ABPI, to find out. From COVID-19 and Brexit, …

NICE methods and process review aims to create fertile ground for innovation Read More »

Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media. Although Irvine Scientific joined parent company Fujifilm in 2018, its roots can be traced back to the 1970s, where it started …

Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company Read More »

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’.  But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. While pharma companies grapple with the effects of Brexit, there are undoubtedly …

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector? Read More »

Health tech and digital transformation lessons from the NHS

In the year since the UK went into its first lockdown to limit the spread of COVID-19 the country’s health service has undergone an unprecedented digital transformation.  The NHS quickly scrambled to reduce face-to-face contact between patients and healthcare professionals, and manage demand for services that would soon be overstretched by dealing with the pandemic. …

Health tech and digital transformation lessons from the NHS Read More »

The hidden danger of isolated congenital asplenia

TEAM 4 Travis is an advocacy group with one objective – to ensure it doesn’t take an autopsy to diagnose isolated congenital asplenia. As part of our Patient Insights series, founder Allison Bones tells us why she is determined to stop history repeating itself. When Travis Bones died just days after his fourth birthday, his …

The hidden danger of isolated congenital asplenia Read More »

LEO Pharma’s new R&D lead on driving agility in drug development

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. We spoke to him about the lessons he’s taking from his prior jobs into the new role and what it means to be an R&D leader in the modern industry. As global head of research …

LEO Pharma’s new R&D lead on driving agility in drug development Read More »

The meaning of digital innovation: the pharmaphorum podcast

This instalment of the podcast considers the meaning of digital innovation, both in pharma and outside the industry, and features digital transformation leader Edwin Erckens. Even though he is currently working in the HR services sector, Edwin started his career at P&G, moved to Heineken, then held regional and global executive IT and digital roles …

The meaning of digital innovation: the pharmaphorum podcast Read More »

Gamification for patient care, medical education, and virtual engagement

“Gamification” – adding game-like elements into non-game or real-world settings – has become a popular concept in the pharmaceutical, healthcare, and event industries, especially as virtual engagement becomes more common during COVID-19. However, it is proving more than a mere buzzword. With diverse applications and approaches, it is quickly becoming a promising tool for patient …

Gamification for patient care, medical education, and virtual engagement Read More »

Could a smartphone cough app stop future pandemics?

A host of companies are looking at cough apps to detect the presence of COVID-19. But one company called Hyfe wants to take the idea a step further and use them to detect future pandemics, reports Richard Staines.  The pandemic has seen a plethora of digital tools emerge to help manage patients remotely, with the …

Could a smartphone cough app stop future pandemics? Read More »

Could a smartphone cough app stop future pandemics?

A host of companies are looking at cough apps to detect the presence of COVID-19. But one company called Hyfe wants to take the idea a step further and use them to detect future pandemics, reports Richard Staines.  The pandemic has seen a plethora of digital tools emerge to help manage patients remotely, with the …

Could a smartphone cough app stop future pandemics? Read More »

The rise of real-world evidence: unlocking the potential in EHRs

The COVID-19 pandemic has demonstrated the importance of health data and how its availability in real time can reveal new insights and innovations that can improve health outcomes for patients. International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health …

The rise of real-world evidence: unlocking the potential in EHRs Read More »

The rise of real-world evidence: unlocking the potential in EHRs

The COVID-19 pandemic has demonstrated the importance of health data and how its availability in real time can reveal new insights and innovations that can improve health outcomes for patients. International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health …

The rise of real-world evidence: unlocking the potential in EHRs Read More »

The host immune response in COVID-19 and beyond

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. The entire healthcare sector experienced a steep learning curve after the outbreak of COVID-19. The pace of work in the industry reached almost ludicrous speeds. Decisions that used to take months …

The host immune response in COVID-19 and beyond Read More »

Patient involvement in trial design: looking to the future

COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. Speakers at the NIHR’s recent virtual event for the pharma industry discussed best practices for bringing patient insights into research. The pandemic has forced the industry to embrace virtual patient …

Patient involvement in trial design: looking to the future Read More »

Life sciences must become cloud-first to seize the science of tomorrow

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And that dynamism, innovation and collaboration are all qualities that the industry must continue to nurture …

Life sciences must become cloud-first to seize the science of tomorrow Read More »

New ways to treat COVID: the pharmaphorum podcast

In episode 31 of the pharmaphorum podcast, Deep Dive editor George Underwood speaks to RedHill biopharma’s chief business officer Guy Goldberg about the potential for new COVID-19 therapeutics to help fight the pandemic and treat patients in the years to come. Prior to joining RedHill, Guy served as senior vice president of business operations at …

New ways to treat COVID: the pharmaphorum podcast Read More »

AI, big data and deep real-world evidence – the challenges and opportunities

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes. An important source of RWE has, until recently, been locked in the electronic health record (EHR). Now, artificial intelligence …

AI, big data and deep real-world evidence – the challenges and opportunities Read More »

Pharma must adapt to embrace the opportunities of a new-look NHS

Fundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to adapt to this new way of working. A new focus on “place” and the introduction of medicines registers are among the proposals in a new government white paper on the future of NHS England. Such changes may …

Pharma must adapt to embrace the opportunities of a new-look NHS Read More »

Inside the UK’s leading efforts to restart clinical research

A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework. Experts from the institute tell us how those numbers can be further boosted, and how lessons learned from the sector-wide collaboration will change UK research forever. There has been a remarkable …

Inside the UK’s leading efforts to restart clinical research Read More »

Why pharma isn’t yet achieving digital excellence, and how it can get there

Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. COVID has seen pharma sales experience three years’ worth of digital transformation in …

Why pharma isn’t yet achieving digital excellence, and how it can get there Read More »

The Alderley Park Discovery Podcast: The journey to accessing science funding and investment

Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract investors. In this instalment, Dominic Tyer is joined by Kinomica CEO Jane Theaker, BioCity investment director Claire Brown, Redx Pharma CEO Lisa Anson and Dr Kath Mackay, managing director at Bruntwood …

The Alderley Park Discovery Podcast: The journey to accessing science funding and investment Read More »

Lymphoma Action – championing the patient voice in cell therapy

Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill and Director of Operations and External Affairs Stephen Scowcroft believe it is essential to champion the patient voice in cell therapy. This thought leadership series has been paid for and developed with Kite, A Gilead Company. Lymphoma …

Lymphoma Action – championing the patient voice in cell therapy Read More »

Focus on Rare: the invisible burden of rare diseases

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Over the past decade there has been considerable investment by pharma into research for rare disease as the patient voice and advocacy movement have done an outstanding job of raising …

Focus on Rare: the invisible burden of rare diseases Read More »

International Women’s Day: The gender gap in clinical trials

For International Women’s Day, Medidata’s global compliance and strategy lead Fiona Maini discusses the importance of increasing female participation in clinical trials and how technology may solve some of the barriers. Although women’s social and political advancement may be progressing across the world, the pharmaceutical industry still has a gender gap at each stage of …

International Women’s Day: The gender gap in clinical trials Read More »

Could personalised medicine change treatment for migraine?

The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific mutations making it to market. Alec Mian, CEO at diagnostics firm Curelator, spoke to pharmaphorum’s news editor Richard Staines about the company’s plans to apply a similar paradigm to other diseases such as migraine.  There has been …

Could personalised medicine change treatment for migraine? Read More »

Health Innovators: Owlstone Medical’s Billy Boyle on breath biopsy technology

In the latest episode of our Health Innovators series, Paul Tunnah speaks to Billy Boyle, co-founder and CEO of Owlstone Medical, one of the UK’s most promising diagnostic startups. The Cambridge, UK-based company is on a mission to save 100,000 lives and $1.5bn in healthcare costs with its breath biopsy platform for early detection of …

Health Innovators: Owlstone Medical’s Billy Boyle on breath biopsy technology Read More »

The post-COVID face of pharma research and development

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response to some long-standing issues with the clinical trials process.  Lockdown rules and safety protocols certainly made it harder for patients to travel to trial sites, while a refocusing …

The post-COVID face of pharma research and development Read More »

Why AI equity is the next step for transformational pharma

AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approaches that only work for specific populations. Intouch Group’s Abid Rahman explains this concept of AI equity and gives some practical tips for how …

Why AI equity is the next step for transformational pharma Read More »

How accidental advocacy is amplifying the GM1 voice

Rare disease families need to stand up and be counted if they want things to change said mum and advocate Christine Waggoner. She spoke to pharmaphorum as part of our Patients Insights series. Like many “rare disease mums”, Christine is an accidental advocate. After her daughter, Iris, was diagnosed with a rare disease at five, …

How accidental advocacy is amplifying the GM1 voice Read More »

How advanced technology can streamline the COVID-19 vaccine rollout

Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants.  While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over. …

How advanced technology can streamline the COVID-19 vaccine rollout Read More »

2021 market access prospects for France

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in France. In September 2020, the French government published the draft of their annual review of spending on health and social care, which will form the basis of …

2021 market access prospects for France Read More »

Health at every size – making medicine weight inclusive

UK-based doctor, Dr Natasha Larmie is on a mission to make medicine weight inclusive. Inspired by the Health at Every Size movement, Natasha is campaigning to take the weighing scales out of general practice and focus instead on health promoting behaviours. Last year, as the pandemic escalated worldwide, UK GP Dr Natasha Larmie embarked on …

Health at every size – making medicine weight inclusive Read More »

Expediting innovation in the rare disease domain

Rare diseases affect a fraction of the population – 450 million+ people globally. However, its effects can be equally severe and life-threatening as other prevalent diseases. For Rare Disease Day, Tarun Kumar Bansal discusses why we need to expedite innovation in the rare disease domain. Every time a patient with a rare condition walks into …

Expediting innovation in the rare disease domain Read More »

Why we need research into the mental health impact of a rare disease diagnosis

Rare diseases impact between 3.5%-5.9% of the world’s population. This Rare Disease Day, RBW Consulting’s Emma Thorp discusses why the consultancy is taking revenue earned from its rare disease clients and using it to fund research into the mental health impact of a rare disease diagnosis. Rare diseases are often chronic and life-threatening, and with a …

Why we need research into the mental health impact of a rare disease diagnosis Read More »

Roche on COVID-19 healthcare and testing: the pharmaphorum podcast

For episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Ireland at Roche Diagnostics, about the pressure COVID-19 has put on healthcare systems. A former NHS doctor, he noted how stressful and draining some days can be when working at healthcare’s frontline – even in normal times, …

Roche on COVID-19 healthcare and testing: the pharmaphorum podcast Read More »

A history of Johnson & Johnson

By most measures the single largest pharma company in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers among the general public.  Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical …

A history of Johnson & Johnson Read More »

Building a better future for people with rare diseases in all four UK nations

How has rare disease care changed over the last few years? And what might we expect from the next five? We attended the Rare Disease Day Virtual Parliamentary Event to find out. The rare disease community has a golden opportunity to transform the way care is delivered across all four UK nations – that’s according …

Building a better future for people with rare diseases in all four UK nations Read More »

Rare disease insights from the patient community

To help pharma companies understand what life is really like for patients with a rare disease, a new resource has been released to coincide with Rare Disease Day 2021. A series of stakeholder interviews have been collected in a new video from Bedrock Healthcare Communications and Origins Insights that explores the underappreciated challenges of living …

Rare disease insights from the patient community Read More »

2021 market access prospects for Spain

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain. In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in Spain. Higher …

2021 market access prospects for Spain Read More »

2021 market access prospects for Germany

The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and what needs reform. In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock …

2021 market access prospects for Germany Read More »

Common but not normal: It’s time to talk about maternal mental health

As part of our Patients Insights series, the founder and CEO of Motherhood Understood shares her experience of postpartum depression, talks about the power of peer support, and explains what the wider healthcare community could do to play their part. Within days of giving birth to her first child, Jen Schwartz’s fairy tale view of …

Common but not normal: It’s time to talk about maternal mental health Read More »

West Africa prepares for Ebola vaccination program

Amidst the COVID-19 pandemic, West Africa is facing a new outbreak of Ebola. A global emergency stockpile of Ebola vaccine is being deployed to curb the epidemic, although experts are confident that synergies in public health practises will ensure a rapid response to both. With a new Ebola outbreak in Guinea declared by health authorities …

West Africa prepares for Ebola vaccination program Read More »

Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4

While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning to shift towards other projects in the big pharma pipeline. pharmaphorum’s news editor, Richard Staines, discusses the success stories and failures in R&D that have emerged during the Q4 results period.  Quarterly results announcements are a good …

Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4 Read More »

No cooling off for pharma digital transformation in 2021

COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life and lighting a fire underneath existing plans that had, in retrospect, yet to burn brightly. After a year in which the need for digital transformation in pharma reached white heat levels, the sector mustn’t cool off in …

No cooling off for pharma digital transformation in 2021 Read More »

Reality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets?

Do your sales reps drive a Ferrari? Probably not. Would they like one if you offered it to them? Probably. Once they were used to driving around in a Ferrari, how easy do you think it would be to convince them to give it back? Nearly impossible. They would argue it is the only way to get to their appointments on time. Nothing else would measure up. So why would …

Reality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets? Read More »

Haven: The strategy that didn’t fix healthcare

John Singer discusses the disbanding of Haven, the joint healthcare venture by Amazon, JP Morgan and Berkshire Hathaway, and the strategies that can help fix US healthcare.  “The market” was terrified when Warren Buffett, Jamie Dimon and Jeff Bezos got together to disrupt healthcare three years ago with the launch of Haven – in response …

Haven: The strategy that didn’t fix healthcare Read More »

4 principles for the future of pharma marketing

COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing? In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model.  “Keith, Kotler, Maslow” has long been the Holy Trinity of pharma marketing. Great ancient thinkers all aspiring marketeers were …

4 principles for the future of pharma marketing Read More »

Why starting an innovation journey isn’t sexy

Chugai Pharmaceutical’s UK innovation lead, Martin Ellgood explores the challenges pharma companies face when devising innovation strategies. On a hot July morning, our managing director called me aside for a “quick word”. Five minutes later I emerged smugly with a new job title: UK innovation lead. I got ready to update my LinkedIn profile. I …

Why starting an innovation journey isn’t sexy Read More »

Ireland is open: The biologics boom boosting the Irish economy

The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of biopharma at Ireland’s economic development agency IDA Ireland tells pharmaphorum why business is blossoming in the Emerald Isle. With an attractive corporate tax rate and the youngest workforce in the …

Ireland is open: The biologics boom boosting the Irish economy Read More »

Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems

Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs.  Ipsen’s John Chaddock tells us why the company is investing heavily in neurotoxin research and how he hopes to raise awareness among young scientists and the NHS. When the COVID-19 pandemic first hit, …

Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems Read More »

Richard Francis on his Purespring plans: the pharmaphorum podcast

In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month. Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma …

Richard Francis on his Purespring plans: the pharmaphorum podcast Read More »

Health Innovators: Sergey Young on how technology can extend human life

How can humans extend their life span? In the second episode of our Health Innovators series, Paul Tunnah speaks to longevity investor Sergey Young about breakthrough technologies that may overcome the negative effects of ageing. Through his $100m Longevity Vision Fund, Sergey invests in companies developing early diagnostics, precision medicine, digital health solutions, AI-based drug …

Health Innovators: Sergey Young on how technology can extend human life Read More »

Omnichannel customer-centric teams and the future of pharma CRM

If pharma companies are to live up to their decades-old patient-centric promises then marketing budgets need to move from brands and franchises to omnichannel customer-centric teams, according to one digital transformation leader. The industry is making some progress with this, but it’s not enough, says Edwin Erckens, who was until recently chief information officer within …

Omnichannel customer-centric teams and the future of pharma CRM Read More »

Increasing patient engagement with UK clinical trials

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. Patient engagement can help address long-running industry issues, such as recruitment and retention, as well as reducing the need for additional trial …

Increasing patient engagement with UK clinical trials Read More »

Stay calm and carry on: How to implement the updated ABPI code

Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to take stock and prioritise. Compliance managers have less than six months to rewrite processes and procedures in line with the updated ABPI code of practice before it becomes enforceable in July. But it doesn’t all have to …

Stay calm and carry on: How to implement the updated ABPI code Read More »

VPAS: Achievement so far on objectives for the economy and innovation

In the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third VPAS objective that relates to the economy and innovation. The objectives for the economy and innovation are to: deliver a net benefit to the UK economy overall; and support the …

VPAS: Achievement so far on objectives for the economy and innovation Read More »

Why we need the human element of remote clinical trials

Over the last year, we’ve noticed that “connectivity” doesn’t always equate to “connected” – and that’s just as true in the realm of clinical trials as it is in our personal lives. Amanda Barrell reports from a panel at the Patients as Partners Europe conference on remote clinical trials. Decentralised trials have been growing in …

Why we need the human element of remote clinical trials Read More »

VPAS: Achievements so far on affordability

In the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the second VPAS objective that relates to affordability (spoiler alert: government gets millions in payments). The affordability objective is broken down further to: ensure that the Voluntary Scheme contributes to …

VPAS: Achievements so far on affordability Read More »

Casting aside CRISPR scissors and making a point with base editors

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies. While achieving the Nobel Prize spotlight would have been enough to …

Casting aside CRISPR scissors and making a point with base editors Read More »

Virtual trials and the next generation of pharma clinical research

Previously viewed as a ‘nice to have’ for the pharma industry, virtual trials were already moving from a theoretical to a practical proposition before COVID-19 accelerated their transition. Studies that follow a virtual, decentralised, hybrid or remote model can offer many patient recruitment benefits including improvements in terms of enabling a more diverse patient population …

Virtual trials and the next generation of pharma clinical research Read More »

Assessing the impact of prevalence on pricing of rare disease drugs in Germany

In this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss the role that disease rarity plays in reimbursement decisions among payers in Germany. Historically, payers have accepted factors including small target patient populations and high clinical development costs as justifications for the high prices of rare disease …

Assessing the impact of prevalence on pricing of rare disease drugs in Germany Read More »

2021 market access prospects for Italy

Italy was working up big changes in market access throughout 2020 which will be implemented in 2021. In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in Italy. AIFA, the Italian Medicines Agency and the agency tasked …

2021 market access prospects for Italy Read More »

AstraZeneca on diversity: the pharmaphorum podcast

The theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by AstraZeneca’s Rebekah Martin. Serving as senior vice president of reward and inclusion at AstraZeneca, Rebekah discussed how the pharmaceutical industry approaches the promotion of diversity. In an episode that was recorded in December 2020, she also talked …

AstraZeneca on diversity: the pharmaphorum podcast Read More »

Gene editing: beyond the hype

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. ‘Cutting edge’ is, for once, a truly …

Gene editing: beyond the hype Read More »

COVID drives a customer experience shift in life sciences CRM

The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. Gartner’s’ CRM market guide notes that AI, digital scalability and hyper-automation hold the keys …

COVID drives a customer experience shift in life sciences CRM Read More »

COVID drives a customer experience shift in life sciences CRM

The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. Gartner’s’ CRM market guide notes that AI, digital scalability and hyper-automation hold the keys …

COVID drives a customer experience shift in life sciences CRM Read More »

Patients as Partners Europe: Are we doing patient centricity all wrong?

To be truly patient centric, do we need to turn the current model on its head and work within a more free-thinking, free-speaking framework? Amanda Barrell reports from Patients as Partners Europe. Despite huge progress over the last decade, patient involvement in research is still largely in the hands of the pharmaceutical companies. That is …

Patients as Partners Europe: Are we doing patient centricity all wrong? Read More »

The US biosimilar market: Predictions for 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. As we’ve seen over those five years, biosimilars are critical in continuing to provide …

The US biosimilar market: Predictions for 2021 Read More »

Unlocking health data to improve oncology outcomes

As the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial health data and real-world evidence (RWE) environment. It’s one that has global potential to improve patient outcomes but efforts to harness the true potential of these information flows are only just beginning. The foundation for this is …

Unlocking health data to improve oncology outcomes Read More »

What we’re expecting in 2021, and beyond…

From telehealth to digital trials, customer engagement to healthcare data, Healthware Group outlines the key trends that are expected to shake up digital health this year. Well, it goes without saying, COVID-19 has resulted in a rapid adoption of digital technologies across all industries, most notably in healthcare. There are several important aspects to these …

What we’re expecting in 2021, and beyond… Read More »

Clinical research in 2021: A new era of collaboration and innovation

The clinical research community has been disrupted in a number of ways due to COVID-19 and sparked a spirit of collaboration and innovation. Worldwide Clinical Trial’s Aman Khera gives five predictions of how clinical research could change in 2021. The pandemic has propelled the life science industry toward higher expectations for faster, more responsive and …

Clinical research in 2021: A new era of collaboration and innovation Read More »

Patient partnerships: putting relevance into relationships

There are perhaps two ways to look at 2020 – on the surface, it has been a year of pandemic health catastrophe, on a deeper level it has been a year where we finally acknowledged the fragility of health partnerships and the importance of good relationships between the pharmaceutical industry and the patients it serves. …

Patient partnerships: putting relevance into relationships Read More »

Biden administration – What can the healthcare industry expect?

As Joe Biden takes the reins at the White House, pharmaphorum asks experts how his presidential tenure may influence the global healthcare industry. “I think the Biden administration will have only an incremental impact on the healthcare industry as a whole,” said Maxim Jacobs, CFA, managing partner and director of research at Edison Group. “With …

Biden administration – What can the healthcare industry expect? Read More »

Assessing physician practices and expectations in the post-COVID era

The ongoing COVID-19 pandemic has affected the routines of many practicing physicians, including an impact on their prescribing decisions. New research from CRA shows that for many physician practices, prescribing has shifted based on route of administration. These changes, initially presumed to be temporary, may continue beyond the pandemic. As several COVID-19 vaccine candidates progress …

Assessing physician practices and expectations in the post-COVID era Read More »

3 practical steps for improving patient support

Research Partnership’s Emilie Braund and Harrison Gaiger dig down into the top insights pharma companies can harness to make their patient support programmes as powerful as possible. The pandemic has undoubtedly disrupted the healthcare landscape and amplified the complex factors that influence and shape patient journeys. Findings from our recently published whitepaper ‘Free thinking: The …

3 practical steps for improving patient support Read More »

Health literacy needs support, now more than ever

The COVID-19 pandemic has brought healthcare guidelines and scientific advances front-of-mind on a global scale, in the process highlighting long-standing gaps in health literacy as well as an opportunity for pharma. It’s long been known that many people struggle to access, understand and use health information and services to make decisions about their health. As …

Health literacy needs support, now more than ever Read More »

Plugging modular content into pharma’s omnichannel strategies

86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating a greater volume of content now, compared to six months ago.  Yet while many pharma companies are creating more content than ever before, they also face increased pressure to quickly deliver highly personalised – and compliant – content …

Plugging modular content into pharma’s omnichannel strategies Read More »

Unlocking the potential in rare disease research with decentralised trials

A survey by rare disease patient network Raremark found that 86% of the community members asked were interested in taking part in clinical trials. CEO Jeremy Edwards looks at how decentralised trial models can solve some of the challenges for clinical trial recruitment in rare disease. With low and geographically dispersed patient populations in rare …

Unlocking the potential in rare disease research with decentralised trials Read More »

Pharma digital transformation: customer data expected to play a pivotal role

A new survey highlights the importance of customer reference data to digital transformation and analyses ways pharma companies can improve the quality of their datasets. In a remote world, customer data is more foundational than ever, and Veeva’s 2020 European Customer Reference Data Survey found 91% of organisations view customer data as a global strategic …

Pharma digital transformation: customer data expected to play a pivotal role Read More »

The elective care conundrum – can digital innovation help?

Karina Malhotra from Acumentice explores how digital tech and data could help address the NHS elective care backlog in 2021 and beyond. The repercussions of the COVID-19 pandemic are going to take a considerable time to repair and nowhere is this more pertinent than in NHS elective care. The impact on elective care has been …

The elective care conundrum – can digital innovation help? Read More »

A collaborative approach to greater diversity in clinical trials

The need for diversity in clinical trial populations has been a topic of discussion across regulators and the industry in general for decades. Despite the introduction of US policies, beginning with the 1993 National Institutes of Health (NIH) Revitalization Act which called for the inclusion of more women and communities of colour in clinical trials, …

A collaborative approach to greater diversity in clinical trials Read More »

A new approach to COVID-19 treatment

While pharma has raced to develop COVID-19 vaccines, US-based company NeuroRx is taking a different approach to treating the virus. CEO Dr. Jonathan Javitt tells pharmaphorum about the science behind the company’s Zyesami, which targets the alveolar type II cells in the lung that are critical for transmission of oxygen. Zyesami was developed in conjunction …

A new approach to COVID-19 treatment Read More »

GSK’s Neale Belson on building trust with employees and society

Pharma’s reputation is currently riding high as the industry comes together to tackle COVID-19, but GSK’s UK general manager Neale Belson says there is always more companies can do to build their culture and make sure employees and customers trust they are doing the right thing. When we spoke with Belson about the GSK’s response …

GSK’s Neale Belson on building trust with employees and society Read More »

Enabling new models of care: pursuing pharma’s partnership potential

There is a huge, ongoing shift in how health and wellness is approached in the UK, and the changes will have important implications for NHS-industry partnerships. Transformative change is coming to the NHS and is set to radically alter how the UK’s health service cares for people at a population level. The NHS Long Term …

Enabling new models of care: pursuing pharma’s partnership potential Read More »

Nine for 2021: Addressing the pandemic legacy

In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: the permanent changes in customer engagement models, the implications of a geographic re-balancing towards the East, CNS as the new value growth area for the 2020s, and the new biologics environment as biosimilars accelerate. …

Nine for 2021: Addressing the pandemic legacy Read More »

Coordinating and delivering research in the pandemic: The UK approach

The acute phase of the COVID-19 pandemic tested the UK’s capacity and capability to rapidly deliver crucial clinical research at a time of immense pressure and stress on personnel and resources. It triggered a system-wide response which took the UK’s collaborative culture to new levels. This multi-agency approach enabled unprecedented speed and efficiency in trial …

Coordinating and delivering research in the pandemic: The UK approach Read More »

Are face-to-face medical meetings a thing of the past?

Everything, from exercise classes to pub quizzes, went online last year – and medical education was no exception. In their droves, congresses, conferences, and masterclasses went virtual in a bid to ensure healthcare professionals were supported, up to date, and socially distanced. But is this change here to stay? Are the days of queuing for …

Are face-to-face medical meetings a thing of the past? Read More »

‘No going back’ for clinical trials after COVID

Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result. The next step is ensuring the industry does not regress to old ways of working once the pandemic is over, say Karen McIntyre and Allyson Small. COVID-19 has changed everything for clinical trials – but …

‘No going back’ for clinical trials after COVID Read More »

2021 – UK market access prospects

With a new year comes the opportunity to think ahead for the market access landscape for the coming year. 2020 was a big year for market access initiatives in the UK, many of which are only just starting, and their impact will come through in 2021 and beyond. Looking back at key market access news …

2021 – UK market access prospects Read More »

2021 – The healthcare changes here to stay

2020 was the year that changed everything, and as the new year begins many are wondering what awaits the world in 2021. Impetus Digital co-founder and CEO Natalie Yeadon reflects on the last 12 months and shares her views on the healthcare, research and digital changes that could be here to stay. I think it …

2021 – The healthcare changes here to stay Read More »

How patient insights are changing trial solutions

Patients have been asking for patient-centric trial solutions for years – the industry just hasn’t been listening. That’s according to Medidata’s Anthony Costello, who was bringing patient feedback into product design long before COVID-19. He tells us what insights pharma has been missing out on and how they can be harnessed to build better solutions. …

How patient insights are changing trial solutions Read More »

COVID-19 and the digital pharma marketing revolution

The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Once the global emergency ends, this trend will continue, argues pharmaphorum’s Richard Staines. The global outbreak of COVID-19 has forced businesses to radically change their way of working. Healthcare companies have been …

COVID-19 and the digital pharma marketing revolution Read More »

Resourceful or risky? The UK’s controversial COVID-19 vaccine strategy

As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation. After months of turbulent lockdown measures, the dawn …

Resourceful or risky? The UK’s controversial COVID-19 vaccine strategy Read More »

True patient-focused research through decentralised and hybrid trials

How can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector give their thoughts on the key approaches and technologies that are driving patient engagement forward. With COVID-19 presenting new barriers to running and recruiting for clinical trials, making studies patient-centric is more important now than ever before. …

True patient-focused research through decentralised and hybrid trials Read More »

Why cell therapy manufacture is a team sport

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work This thought leadership series has been paid and developed by Kite, a Gilead Company. In 2018, we were preparing to build …

Why cell therapy manufacture is a team sport Read More »

Boosting the impact of patient services

New research from Accenture has revealed that adoption of patient support services hasn’t improved since 2015 despite increasing pharma investment. The company’s Jennifer Spada tells us how companies can boost awareness of their programmes to improve patient outcomes. As part of its drive towards patient centricity, the pharma industry has increasingly been building patient support …

Boosting the impact of patient services Read More »

The Alderley Park Discovery Podcast: Life science skills, staffing and support

Episode two of the Alderley Park Discovery Podcast covers access to skills in the life sciences sector, with a focus on support for aspiring scientists and UK staffing trends. In this instalment Dominic Tyer’s guests on the podcast are Sai Life Sciences’ head of global R&D Dean Edney, Joynes & Hunt’s managing director Steve Joynes …

The Alderley Park Discovery Podcast: Life science skills, staffing and support Read More »

How Big Data will accelerate the future of digital medicine in 2021

The pandemic has shed light on inefficiencies in healthcare systems, and provided an opportunity to adjust how we manage care in the future. Jennifer Haas, executive vice president of Noteworth, shares her 2021 predictions surrounding the future of telehealth and big data.  Healthcare providers are grappling with the task of scaling digital care delivery operations …

How Big Data will accelerate the future of digital medicine in 2021 Read More »

5 ways digital health, and digital pharma, changed in 2020

Reviewing 2019’s key digital health stories last year I suggested that, while big strides continued to be made, any definitive ‘coming of age’ moment for the sector was unlikely. But that was before the first reports emerged of a highly contagious coronavirus and 2020 will be forever associated with COVID-19 and the global devastation and …

5 ways digital health, and digital pharma, changed in 2020 Read More »

J&J and medical device innovation: the pharmaphorum podcast

In episode 27 of the pharmaphorum podcast I’m joined by Erin McEachren, who’s EU regional vice president at J&J Surgical Vision. She talks about her priorities at J&J – having joined the company six months ago, the current state of the medical devices sector and some of the trends she’s keeping a close eye on. …

J&J and medical device innovation: the pharmaphorum podcast Read More »

2020 in review: COVID-19 and patient centric clinical trials

The trials and tribulations of 2020 have brought the vital role of research, pharma, and biotech into sharp focus. But how has the push to develop treatments and vaccines for SARS-CoV-2 affected the industry’s commitment to patient centricity? This time last year, researchers and industry players were working hard to embed patient centricity and engagement …

2020 in review: COVID-19 and patient centric clinical trials Read More »

Moderna and BioNTech – who are they?

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, asks Richard Staines. A year ago, the names Moderna and BioNTech were known mainly to those who followed biotech and pharma dealings. But the …

Moderna and BioNTech – who are they? Read More »